LINK Medical AS og Melanor inngår samarbeidsavtale
LINK Medial AS og Melanor har inngått samarbeidsavtale som gir medlemmer tilgang til nødvendig kompetanse og rådgiving på gunstige vilkår i prosessen mot registering av medisinsk utstyr.
Categories: innovation
-
-
The patient recruitment milestone has been reached for AlzeCure's Phase II clinical trial in neuropathic pain with non-opioid ACD440
LINK Medical, the Northern European clinical research organization (CRO), and AlzeCureÒ Pharma AB (publ) (FN STO: ALZCUR), announced today that the last patient has been enrolled in the phase II clinical trial for neuropathic pain treated with the non-opioid ACD440.
-
Another milestone reached for AlzeCure's Phase II clinical trial in neuropathic pain with non-opioid ACD440
The first patient has been enrolled in the phase II clinical trial for neuropathic pain treated with the non-opioid ACD440. The Phase II clinical trial is a double-blind, placebo-controlled, randomized cross-over study evaluating the efficacy, safety, and pharmacokinetics of AlzeCure's leading drug candidate in pain, ACD440. Results from the study are expected in mid-2023.
-
Full-service CRO LINK Medical and Viedoc™ sign a new partnership agreement
LINK Medical and Viedoc announced today a new Partnership Program between the two companies. The Partnership Program established by Viedoc is designed to improve trial efficiency for LINK Medical and its clients. It allows for continuous exchange of experience, needs, and ideas, as well as testing of new features.
